Atlas Trials

Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer

Clinical trial NCT06009848 · UNKNOWN

Trial details

NCT number
NCT06009848
Sponsor
Tianjin Medical University Second Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder Cancer
Start date
2022-10-10
Primary completion
2025-10-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.